Details of the webinars are as follows:
Diving Deep into TREM2: Uncovering its Potential as a Therapeutic Target for Alzheimer’s Disease
Alector’s management team will be joined by:
Michael Heneka , M.D., Director of theLuxembourg Centre for Systems Biomedicine (LCSB) at theUniversity of Luxembourg and Adjunct Professor at theUniversity of Massachusetts Chan Medical School Reisa Sperling , M.D., Professor of Neurology atHarvard Medical School and Director of theCenter for Alzheimer Research and Treatment at Brigham and Women’s Hospital andMassachusetts General Hospital
A Detailed Review of PGRN: A
Alector’s management team will be joined by:
Fenghua Hu , Ph.D., Associate Professor,Department of Molecular Biology and Genetics andWeill Institute for Cell and Molecular Biology atCornell University Adam Boxer , M.D., Ph.D., Endowed Professor in Memory and Aging in theDepartment of Neurology at theUniversity of California, San Francisco
A live question and answer session will follow the formal presentations. To access the live webcasts of these events, please register here for TREM2 and here for PGRN, or visit “Events and Presentations” in the “Investors” section of the Alector website at https://investors.alector.com. An archived replay will be available for approximately 90 days following each presentation.
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, planned and ongoing preclinical studies and clinical trials and the timing of data readouts from such trials, expected milestones, expectations of our collaborations, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector’s Quarterly Report on Form 10-Q filed on
Alector Contacts:
Alector
202-549-0557
katie.hogan@alector.com
1AB (media)
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
212.600.1902
alector@argotpartners.com
Source:
2023 GlobeNewswire, Inc., source